ETF · SPDR · XBI
State Street SPDR S&P Biotech ETF
State Street SPDR S&P Biotech ETF (XBI) is an ETF from SPDR that tracks the S&P Biotechnology Select Industry Index index. Its ongoing charge is 0.35% a year and it holds $10.2bn in assets. The fund uses physical replication, is distributing, is domiciled in United States.
XBI in figures
- Assets
- $10.2bn
- Ongoing charge (TER)
- 0.35%
- Holdings
- 165
- Weight of the ten largest
- 18.4%
- Dividend yield
- 0.1%
- Return, year to date (USD)
- +23.6%
- Return, 1 year (USD)
- +35.1%
- Return, 3 years a year (USD)
- +28.8%
- Return, 5 years a year (USD)
- +3.7%
- Volatility, 3 years (USD)
- 28.1%
Figures as of 13 November 2026. Past performance does not predict future returns. Information only, not investment advice.
Fund facts
- Issuer
- SPDR
- Index
- S&P Biotechnology Select Industry Index
- Asset class
- Equity, Sector
- Region
- US
- Replication
- Physical
- Income
- distributing
- Domicile
- United States
- Currency hedged
- No
- Launched
- 6 February 2006
- ISIN
- US78464A8707
Largest holdings
| MODERNA INC | 2.7% |
| EXELIXIS INC | 1.8% |
| AMGEN INC | 1.8% |
| BIOGEN INC | 1.8% |
| GILEAD SCIENCES INC | 1.8% |
| ABBVIE INC | 1.8% |
| HALOZYME THERAPEUTICS INC | 1.8% |
| REGENERON PHARMACEUTICALS | 1.7% |
| UNITED THERAPEUTICS CORP | 1.7% |
| SPYRE THERAPEUTICS INC | 1.7% |
Sectors
| Healthcare | 99.3% |
| Financial Services | 0.7% |
Countries
| United States | 96.8% |
| Switzerland | 1.4% |
| United Kingdom | 1.3% |
| Netherlands | 0.5% |
| Ireland | 0.1% |
| China | 0.0% |